---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: American hospital formulary service (AHFS), or other drug classification"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: American hospital formulary service (AHFS), or other drug classification. Topics: WHO INN class statement for claseprubart, WHO INN stem and target-class infix for monoclonal antibodies, and WHO Anatomical Therapeutic Chemical group for complement inhibitors. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/american-hospital-formulary-service-ahfs-or-other-drug-classification"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: American hospital formulary service (AHFS), or other drug classification

<a id="heading-2.1.2.4"></a>

## 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

### WHO INN class statement for claseprubart

> “claseprubart”
> “immunosuppressant”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.4-2"></a>

### WHO INN stem and target-class infix for monoclonal antibodies

> “The suffix is preceded by an infix that indicates the target class.”
> “The suffix -bart is used for monospecific full-length immunoglobulins with engineered amino acid changes in the constant regions and identical sets of CDRs that recognize the same epitope.”
> “altered neonatal Fc receptor (FcRn) binding”
> “-pru- immunosuppressive”

Source: [WHO INN monoclonal antibody nomenclature scheme (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-_2021rev.pdf)

<a id="topic-2.1.2.4-3"></a>

### WHO Anatomical Therapeutic Chemical group for complement inhibitors

| ATC code | Name |
| --- | --- |
| “L04AJ” | “Complement inhibitors” |
| “L04AJ01” | “eculizumab” |
| “L04AJ02” | “ravulizumab” |
| “L04AJ04” | “sutimlimab” |
| “L04AJ06” | “zilucoplan” |

Source: [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L04AJ)

<a id="topic-2.1.2.4-4"></a>

### AHFS class and ATC code assigned to claseprubart

No evidence found.

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
